Published in N Engl J Med on March 25, 2013
Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) | NCT02007239
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol (2014) 3.94
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol (2013) 3.65
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Cell (2016) 2.84
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med (2015) 2.77
Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
Current concepts in the diagnosis and management of cytokine release syndrome. Blood (2014) 2.63
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science (2015) 2.50
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood (2013) 2.39
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov (2015) 2.29
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res (2014) 2.25
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell (2016) 2.15
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood (2013) 2.13
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol (2015) 2.11
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol (2015) 2.07
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Chimeric antigen receptor therapy for cancer. Annu Rev Med (2013) 1.94
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med (2015) 1.91
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med (2015) 1.87
Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev (2014) 1.86
Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell (2016) 1.82
Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med (2015) 1.82
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell (2015) 1.74
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood (2016) 1.69
Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy (2014) 1.67
Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses. Blood (2014) 1.65
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood (2014) 1.64
Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J (2014) 1.64
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol (2013) 1.64
Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood (2015) 1.53
Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood (2015) 1.52
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia (2013) 1.52
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood (2014) 1.52
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Toxicities of Immunotherapy for the Practitioner. J Clin Oncol (2015) 1.50
Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci Transl Med (2015) 1.49
Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma. Clin Cancer Res (2015) 1.48
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood (2016) 1.47
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol (2013) 1.46
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo. Leukemia (2015) 1.45
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer Immunol Res (2016) 1.44
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med (2014) 1.44
Radiation and immunotherapy: a synergistic combination. J Clin Invest (2013) 1.44
T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1. Cytotherapy (2014) 1.43
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol (2014) 1.38
IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest (2013) 1.36
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood (2015) 1.35
Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol (2013) 1.34
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev (2014) 1.33
Immunotoxins for leukemia. Blood (2014) 1.33
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia (2014) 1.32
A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.32
International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med (2016) 1.29
CAR T cells for solid tumors: armed and ready to go? Cancer J (2014) 1.29
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol (2015) 1.27
IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol (2014) 1.27
Individual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells. Cancer Immunol Res (2015) 1.25
Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther (2013) 1.25
Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer (2016) 1.22
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res (2013) 1.22
Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther (2013) 1.21
CAR therapy: the CD19 paradigm. J Clin Invest (2015) 1.20
Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr (2014) 1.19
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov (2015) 1.18
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest (2016) 1.18
Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother (2014) 1.17
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant (2013) 1.13
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res (2015) 1.13
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood (2014) 1.11
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst (2016) 1.11
Synthetic Nanoparticles for Vaccines and Immunotherapy. Chem Rev (2015) 1.10
The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov (2015) 1.09
CD19-CAR trials. Cancer J (2014) 1.09
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A (2016) 1.09
Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol (2015) 1.09
Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia (2015) 1.09
Driving CAR T-cells forward. Nat Rev Clin Oncol (2016) 1.09
Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A (2016) 1.08
Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther (2014) 1.08
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Front Immunol (2015) 1.08
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Toxicities of chimeric antigen receptor T cells: recognition and management. Blood (2016) 1.07
Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol (2014) 1.07
Vaccines, new opportunities for a new society. Proc Natl Acad Sci U S A (2014) 1.06
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther (2013) 1.06
Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med (2015) 1.06
Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther (2014) 1.06
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res (2016) 1.05
Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther (2014) 1.05
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood (2008) 7.01
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 5.30
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 4.51
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant (2010) 3.79
Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med (1994) 3.26
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell (2008) 2.78
Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med (2012) 2.73
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood (2012) 2.27
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res (2010) 1.84
Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest (2011) 1.75
Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol (2008) 1.75
Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant (2000) 1.62
Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Res (2005) 1.55
Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am (2001) 1.38
Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant (2011) 1.37
Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol (1993) 1.36
IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. J Invest Dermatol (2012) 1.26